evidence:  The distributions of the Kaplan–Meier curves for the two treatment groups were significantly different, with the probability of persistence significantly higher in the ibandronate/PSP group (p < 0.0001, log-rank and Wilcoxon–Gehan tests)
intervention:  ibandronate plus a patient support programme (PSP)
comparator: alendronate
outcome: persistence on treatment